Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kung-I Feng"'
Autor:
Anette Müllertz, Andrew Leithead, Thomas Rades, Kung-I Feng, Søren Astrup Jørgensen, Nicole Canfield, Cecilie Maria Madsen
Publikováno v:
European Journal of Pharmaceutical Sciences. 111:311-319
The composition of the human intestinal fluids varies both intra- and inter-individually. This will influence the solubility of orally administered drug compounds, and hence, the absorption and efficacy of compounds displaying solubility limited abso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d3a6f461c7bd5de57cef2e3f30200c
https://doi.org/10.1016/j.ejps.2017.10.003
https://doi.org/10.1016/j.ejps.2017.10.003
Autor:
Richard Tschirret-Guth, Caroline McGregor, Mark Cartwright, Michael D. Altman, Suman Mukherjee, Iain Martin, Alan B. Northrup, Pierre Daublain, Kung-I Feng, Rebecca Nofsinger
Publikováno v:
Molecular Pharmaceutics. 14:1634-1645
The purpose of this research was to assess variability in pharmacokinetic profiles (PK variability) in preclinical species and identify the risk factors associated with the properties of a drug molecule that contribute to the variability. Exposure da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a62ebcee6b50d075d33266387a1cf7
https://doi.org/10.1021/acs.molpharmaceut.6b01118
https://doi.org/10.1021/acs.molpharmaceut.6b01118
Autor:
Jianzhong Wen, Nicole Buist, Ying Li, Scott Fauty, Prajakta Gadgil, Marian E. Gindy, Alexei V. Buevich, Tomi K. Sawyer, Candice Alleyne, Mengwei Hu, Kung-I Feng, Gino Salituro, Rebecca Nofsinger
Publikováno v:
Pharmaceutical Research. 36
In this study we evaluated the utility of in-vitro screening tools for predicting the in-vivo behavior of six cyclic peptides with different solubility and permeability properties (BCS class II and III), intended for oral delivery in presence of perm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aaa5891ad32051a85a09259c8b1610c
https://doi.org/10.1007/s11095-019-2682-8
https://doi.org/10.1007/s11095-019-2682-8
Autor:
Xing Dai, Steven W. Ludmerer, Hong Liu, Fangbiao Li, Linda Brockunier, Anandan Palani, Kung-I Feng, Shuwen He, Ravi P. Nargund, Karen Marcantonio
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(24)
Hepatitis C virus (HCV) NS5B polymerase is a prime target for the development of direct-acting antiviral drugs for the treatment of chronic HCV infection. Several novel and potent HCV NS5B non-nucleoside inhibitors with unique tetracyclic bezonfuran-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b630ae7fab4a5cf6d900c96c69f0b183
https://pubmed.ncbi.nlm.nih.gov/30389294
https://pubmed.ncbi.nlm.nih.gov/30389294
Autor:
Shiying Chen, Mark Cartwright, Joseph A. Kozlowski, Lei Chen, Tao Ji, Ling Tong, Patricia McMonagle, Wensheng Yu, Frederick C. Lahser, Laura L. Rokosz, Rong Liu, Kung-I Feng, Bin Hu, Jingjun Yin, Jinglai Hao, Shuai Zan, Oleg Selyutin, Sony Agrawal, Paul Ingravallo, Rebecca T. Ruck, Bin Zhong, Karin Bystol, Donna Carr, Ernest Asante-Appiah, Stephanie Curry
Publikováno v:
Journal of medicinal chemistry. 61(9)
We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74345b9916767513eae8b25183d4e7b8
https://pubmed.ncbi.nlm.nih.gov/29681153
https://pubmed.ncbi.nlm.nih.gov/29681153
Publikováno v:
Oral Formulation Roadmap from Early Drug Discovery to Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8398afe619e4f8017393eaec19229948
https://doi.org/10.1002/9781118907894.ch6
https://doi.org/10.1002/9781118907894.ch6
Autor:
Jean E. Lachowicz, Kung-I Feng, Joyce J. Hwa, Jitendra D. Belani, Michael Wong, Ling Kang, Diane Grotz, Wensheng Yu, Sue-Ing Lin, Yang Cao, Andrew Stamford, Richard A. Morrison, Peishan Lin, Duane E. DeMong, Hongtao Zhang, Peng Dai, Jolicia Gauuan, Christopher Sondey, Joseph A. Kozlowski, He Zhao, Mark Liang, Ying Zhai, Brian J. Lavey, Xing Dai, Aileen Soriano, Tao Meng, Ping Chen, De-Yi Yang, William J. Greenlee, Bradley Prudence K, Kathleen Cox, Bhuneshwari Patel, Paul McNamara, Jesse K. Wong, Michael W. Miller, Guowei Zhou, Teresa Andreani
Publikováno v:
Journal of Medicinal Chemistry. 57:2601-2610
A novel series of spiroimidazolone-based antagonists of the human glucagon receptor (hGCGR) has been developed. Our efforts have led to compound 1, N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazasp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d79521da6469de081b15fb4cf46d71d
https://doi.org/10.1021/jm401858f
https://doi.org/10.1021/jm401858f
Autor:
Richard W. Chapman, Kung-I Feng, Aileen House, James Lamca, Robert G. Aslanian, Chander S. Celly, Rongze Kuang, Danlin Gu, Ping Wu, Zhidan Liu, Jianhua Cao, Daniel Prelusky, Ying Huang, Jonathan E. Phillips, Pauline C. Ting, Peng Wang, Daniel Lundell, Joe F. Lee
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:5528-5532
The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discusse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddbd43258d2126bb9cc464f96ed173f1
https://doi.org/10.1016/j.bmcl.2013.08.056
https://doi.org/10.1016/j.bmcl.2013.08.056
Autor:
Jiayi Xu, Thomas Bateman, Patrick Andre, Wayne M. Geissler, Joseph M. Metzger, Harold B. Wood, Manash Shankar Chatterjee, Wendy Ankrom, Kung‐I Feng, Marija Tadin-Strapps, Dietmar Seiffert, Walter Strapps
Publikováno v:
Pharmacology Research & Perspectives
The benefits of novel oral anticoagulants are hampered by bleeding. Since coagulation factor IX (fIX) lies upstream of fX in the coagulation cascade, and intermediate levels have been associated with reduced incidence of thrombotic events, we evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb17b86041e31adee5944c59aa83285a
https://doi.org/10.1002/prp2.207
https://doi.org/10.1002/prp2.207
Autor:
Andrew Stamford, Bernard R. Neustadt, Lindo Neil A, Deen Tulshian, Kwokei Ng, Carolyn Foster, William J. Greenlee, Ennio Ongini, Jean E. Lachowicz, John C. Hunter, Jinsong Hao, Kung-I Feng, Rosalia Bertorelli, Leyla Arik, Angela Monopoli
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:1376-1380
Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea07282f57507d69c232a53821fdf627
https://doi.org/10.1016/j.bmcl.2006.11.083
https://doi.org/10.1016/j.bmcl.2006.11.083